Target therapy in treatment of HER2-positive breast cancer
The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggres...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839579634079891456 |
|---|---|
| author | A. S. Belokhvostova I. A. Smirnova A. A. Enileeva |
| author_facet | A. S. Belokhvostova I. A. Smirnova A. A. Enileeva |
| author_sort | A. S. Belokhvostova |
| collection | DOAJ |
| description | The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggressive course of disease, an early metastasis, resistance to chemo-and hormonotherapy. The main targeted drugs registered in the Russian Federation for treatment of HER2-positive BC is Trastuzumab (herceptin®). The presented review contains data of researches on application of a preparation of herceptin in various schemes of chemotherapy. Studying of a combination of trastuzumab with cytostatics, other targeted drugs proceeds at various stages of tumoral process. |
| format | Article |
| id | doaj-art-c7d22efbb56646cfba4d8ccce9940bc2 |
| institution | Matheson Library |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2016-02-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-c7d22efbb56646cfba4d8ccce9940bc22025-08-04T10:33:35ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-01028488103Target therapy in treatment of HER2-positive breast cancerA. S. Belokhvostova0I. A. Smirnova1A. A. Enileeva2Medical Radiological Research Center of the Russian Ministry of Health and Social DevelopmentMedical Radiological Research Center of the Russian Ministry of Health and Social DevelopmentMedical Radiological Research Center of the Russian Ministry of Health and Social DevelopmentThe breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggressive course of disease, an early metastasis, resistance to chemo-and hormonotherapy. The main targeted drugs registered in the Russian Federation for treatment of HER2-positive BC is Trastuzumab (herceptin®). The presented review contains data of researches on application of a preparation of herceptin in various schemes of chemotherapy. Studying of a combination of trastuzumab with cytostatics, other targeted drugs proceeds at various stages of tumoral process.https://www.siboncoj.ru/jour/article/view/103breast cancerher2trastuzumab (herceptin®) |
| spellingShingle | A. S. Belokhvostova I. A. Smirnova A. A. Enileeva Target therapy in treatment of HER2-positive breast cancer Сибирский онкологический журнал breast cancer her2 trastuzumab (herceptin®) |
| title | Target therapy in treatment of HER2-positive breast cancer |
| title_full | Target therapy in treatment of HER2-positive breast cancer |
| title_fullStr | Target therapy in treatment of HER2-positive breast cancer |
| title_full_unstemmed | Target therapy in treatment of HER2-positive breast cancer |
| title_short | Target therapy in treatment of HER2-positive breast cancer |
| title_sort | target therapy in treatment of her2 positive breast cancer |
| topic | breast cancer her2 trastuzumab (herceptin®) |
| url | https://www.siboncoj.ru/jour/article/view/103 |
| work_keys_str_mv | AT asbelokhvostova targettherapyintreatmentofher2positivebreastcancer AT iasmirnova targettherapyintreatmentofher2positivebreastcancer AT aaenileeva targettherapyintreatmentofher2positivebreastcancer |